Sietske K. Rosendahl Huber
A5091288177- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Immunotherapy and Immune Responses
- Respiratory viral infections research
- Immune Cell Function and Interaction
- SARS-CoV-2 detection and testing
- vaccines and immunoinformatics approaches
- Immune responses and vaccinations
- Immune Response and Inflammation
- Long-Term Effects of COVID-19
- Virus-based gene therapy research
- COVID-19 epidemiological studies
- Cancer Immunotherapy and Biomarkers
- Tuberculosis Research and Epidemiology
- Monoclonal and Polyclonal Antibodies Research
- Vaccine Coverage and Hesitancy
- Diabetes and associated disorders
- COVID-19 diagnosis using AI
Janssen (Netherlands)
2020-2023
Janssen (Switzerland)
2022
Janssen (Belgium)
2020
National Institute for Public Health and the Environment
2014-2019
Amsterdam UMC Location Vrije Universiteit Amsterdam
2011
Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve magnitude durability of immunity protective efficacy. We assessed one- two-dose Ad26.COV2.S candidate in adult aged nonhuman primates (NHPs). A regimen induced higher peak binding neutralizing antibody responses compared with a single dose. In one-dose regimens, were stable for at least...
SUMMARY The hallmark of tuberculosis (TB) is the formation granulomas, which are clusters infected macrophages surrounded by additional macrophages, neutrophils and lymphocytes. Although it has long been thought that granulomas beneficial for host, there evidence mycobacteria also promote these structures. In this study, we aimed to identify new mycobacterial factors involved in initial stages granuloma formation. We exploited zebrafish embryo Mycobacterium marinum infection model study...
Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster non-human primate infection models. Here, investigated the immunogenicity, protective efficacy, potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S moderate challenge model, using currently most prevalent G614 variant. Vaccine...
Omicron spike (S) encoding vaccines as boosters, are a potential strategy to improve COVID-19 vaccine efficacy against Omicron. Here, macaques (mostly females) previously immunized with Ad26.COV2.S, boosted Ad26.COV2.S.529 (encoding BA.1 S) or 1:1 combination of both vaccines. All booster vaccinations elicit rapid antibody titers increase WA1/2020 and S. BA.2 responses most effectively by including Ad26.COV2.S.529. Independent used, mostly WA1/2020-reactive WA1/2020-Omicron cross-reactive B...
Avian influenza A of the subtype H7N9 has been responsible for almost 1600 confirmed human infections and more than 600 deaths since its first outbreak in 2013. Although sustained human-to-human transmission not reported yet, further adaptations to humans viral genome could potentially lead an pandemic, which may have severe consequences due absence pre-existent immunity this strain at population level. Currently there is no (H7N9) vaccine available. Therefore, case a pandemic outbreak,...
Abstract Several COVID-19 vaccines have recently gained authorization for emergency use. Limited knowledge on duration of immunity and efficacy these is currently available. Data other coronaviruses after natural infection suggest that to SARS-CoV-2 might be short-lived, preliminary evidence indicates waning antibody titers following infection. In this work, we model the relationship between immunogenicity protective a series Ad26 vectors encoding stabilized variants Spike protein in rhesus...
Currently licensed influenza vaccines mainly induce antibodies against highly variable epitopes. Due to antigenic drift, protection is subtype or strain-specific and regular vaccine updates are required. In case of shifts, which have caused several pandemics in the past, completely new need be developed. We set out develop a that provides broad range viruses. Therefore, conserved parts A virus (IAV) were selected we constructed antibody T cell inducing peptide-based vaccines. The B epitope...
Influenza CD8(+) T-cell epitopes are conserved amongst influenza strains and can be recognized by influenza-specific cytotoxic T-cells (CTLs), which rapidly clear infected cells. An peptide vaccine that elicits these CTLs would therefore an alternative to current vaccines, not cross-reactive. However, antigens poorly immunogenic due lack of delivery antigen presenting cells, need additional formulation with a suitable system. In this study, the potential virosomes as system for was...
While currently used influenza vaccines are designed to induce neutralizing antibodies, little is known on T cell responses induced by these vaccines. The 2009 pandemic provided us with the opportunity evaluate immune response vaccination in a unique setting. We evaluated both antibody and cohort of public health care workers (18-52 years) during two consecutive seasons from 2009-2011 compared MF59-adjuvanted vaccine unadjuvanted seasonal subunit that included strain (The study was...
T cells are essential players in the defense against infection. By targeting MHC class I antigen-presenting pathway with peptide-based vaccines, antigen-specific can be induced. However, low immunogenicity of peptides poses a challenge. Here, we set out to increase influenza-specific CD8+ cell epitopes. substituting amino acids wild type sequences non-proteogenic acids, affinity for increased, which may ultimately enhance cytotoxic responses. Since preventive vaccines viruses should induce...
Abstract We previously reported that a single immunization with an adenovirus serotype 26 (Ad26) vector-based vaccine expressing optimized SARS-CoV-2 spike (Ad26.COV2.S) protected rhesus macaques against challenge. In this study, we evaluated the immunogenicity and protective efficacy of reduced doses Ad26.COV2.S. 30 were immunized once 1×10 11 , 5×10 10 1.125×10 or 2×10 9 vp Ad26.COV2.S sham challenged by intranasal intratracheal routes. Vaccine as low provided robust protection in...
Influenza peptide antigens coding for conserved T cell epitopes have the capacity to induce cross-protective influenza-specific immunity. Short used as a vaccine, however, often show poor immunogenicity. In this study, we demonstrate that whole inactivated influenza virus (WIV) acts an adjuvant antigens, shown by induction of specific CD8+ cells in HLA-A2.1 transgenic mice upon vaccination with influenza-M1 derived GILGFVFTL (GIL), formulated WIV. By screening various concentrations GIL and...
Abstract Safe and effective coronavirus disease (COVID)-19 vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve magnitude durability of immunity protective efficacy. We assessed one- two-dose Ad26.COV2.S candidate in adult aged non-human primates (NHP). A regimen induced higher peak binding neutralizing antibody responses compared a single dose. In one-dose were stable for at least 14 weeks,...
The first COVID-19 vaccines have recently gained authorization for emergency use. 1,2 At this moment, limited knowledge on duration of immunity and efficacy these is available. Data other coronaviruses after natural infection suggest that to SARS-CoV-2 might be short lived, 3,4 preliminary evidence indicates waning antibody titers following infection. 5 Here we model the relationship between immunogenicity protective a series Ad26 vectors encoding stabilized variants Spike (S) protein in...
ABSTRACT Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster non-human primate infection models. Here, investigated the immunogenicity, protective efficacy potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S moderate challenge model, using currently most prevalent G614 variant....
Abstract Omicron spike (S) encoding vaccines as boosters, are a possible strategy to improve COVID-19 vaccine efficacy against Omicron. Here, non-human primates immunized twenty months earlier with Ad26.COV2.S, were boosted Ad26.COV2.S.529 (encoding BA.1 S) or combination of both vaccines. All elicited rapid increase in WA1/2020 and S antibody titers; BA.2 responses most effectively by including Ad26.COV2.S.529. Independent used, mostly WA1/2020-reactive cross-reactive B cells detected....